SOURCE: Mid Atlantic Bio Angels

Mid Atlantic Bio Angels

October 21, 2013 07:55 ET

Mid Atlantic Bio Angels Announce "Best in Show" of Their 1st Pitch Lifescience Event

Immunovent Is Chosen as "Best in Show" at the Event Where Aspiring Life Science Entrepreneurs Gain the Chance to "Eavesdrop" on Investors' Closed Door Discussions

NEW YORK, NY--(Marketwired - Oct 21, 2013) - Mid Atlantic Bio Angels (www.bioangels.net) announced today the winner of their second 1st Pitch Life Science event, which took place October 2, 2013 in New York, NY. Immunovent, based out of New York City received the title for the "Best in Show" for their well-constructed pitch, innovative product and excellent business model. Immunovent will advance to an annual "Best of the Best/People's Choice" competition along with the "Best in Show" winners from other 1st pitch events.

"My participation in 1st Pitch is to help educate both the presenters and the audience about the demands of the angel marketplace. While each of the presenters offered excellent lessons in what to do (or not do) in a pitch, the choice of Immunovent reflected the maturity and substance of its business plan, as well as the presenter's clear answers to some hard questions. The vote reflected the fact that Immunovent is the closest to being 'ready for prime time'," said Stephen M. Goodman, Esq., Partner, Pryor Cashman LLP (NYC), a 1st Pitch panelist and one of the founders of MABA.

The winning life science company, Immunovent, is reinventing allergy diagnostics with their Local Allergy Mucosal Brush (LAMB) Test, which identifies local antigen-specific igE not found by skin or blood testing. The LAMB test is the only standardizeable and patient-friendly test for local allergic sensitizations. "The panel of experts and enthusiastic audience participation at 1st Pitch NYC gave us the honest and constructive feedback Immunovent needed to take our presentation of the Local Allergy Mucosal Brush (LAMB) test to the next level," said CSO of Immunovent, Kate Rochlin.

1st Pitch Life Science has been organized by MABA, a life science investor group, to encourage and educate aspiring life science entrepreneurs who know they may be too early to seek investment but want the opportunity to practice their pitch and to receive constructive criticism from experienced and knowledgeable professionals in the industry. Three life science companies were selected to present at the event, which was sponsored by: Anchin, Block & Anchin LLP, McCarter & English, SocialRadius and Yorn.

"Three early stage companies presented creative approaches to solve problems they have identified in their fields of work. The inventors and entrepreneurs are to be congratulated on their efforts. Immunovent demonstrated to the investors and entrepreneurs in the voting audience that they have progressed the furthest. Thanks to Mid Atlantic Bio Angels for organizing the 1st Pitch event," said Martin Phillips, MD, CEO Tarnhelm Therapeutics, 1st Pitch panelist and also an investor and Steering Committee member of MABA.

About MABA Mid Atlantic Bio Angels (MABA) is an angel investor group focused exclusively on new and emerging life science companies. Membership in MABA is by invitation only, and is extended to active, accredited investors (life science angels) who wish to make investments in life science companies, as well as institutional investors and life science company venture arms wishing to invest alongside the angels. MABA places no geographical restrictions or requirements for presenting companies, as long as meaningful and effective post-investment monitoring of these companies can be achieved.

For more information: http://bioangels.net

About Immunovent

Immunovent is a NYC-based bioventure that is focusing on commercialization of novel technologies for diagnosing allergies. The company is currently developing the Local Allergy Mucosal Brush (LAMB) Test, a technology that emerged from research at the Weill-Cornell College of Medicine. The LAMB test is the first local allergy test that can conveniently and accurately diagnose the ~25% of respiratory and food sensitivities that fail to be detected by traditional skin- and blood-based allergy testing.

Contact Information

  • Media Contact
    Katherine Chang
    Social Radius on behalf of MABA
    Email Contact